Related Experiment Video
Updated: Aug 5, 2026

Ferric Chloride-induced Thrombosis Mouse Model on Carotid Artery and Mesentery Vessel
Published on: June 29, 2015
Molecular basis of Glanzmann's Thrombasthenia and current strategies in treatment
1Service d'Hématologie Biologique, Hôpital Lariboisière, 2, rue Ambroise Paré, 75010, Paris, France.
Abstract:
Glanzmann Thrombasthenia, an exceptional inherited platelet disorder is characterized by a complete lack of platelet aggregation due to a defect in the alpha(IIb)beta(3) complex or to a qualitative abnormality of this complex. Advances in molecular biology have permitted to precise the molecular abnormality on alpha(IIb) or beta(3) genes responsible for the disease and have also contributed to a better knowledge of normal platelet physiology. Hemorrhages are the main clinical problem. Current principles of therapeutic management are proposed, with special reference to the risk of platelet alloimmunisation.
Related Concept Videos
Blood Transfusion and Agglutination
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Pharmacogenomics: Identification of New Drug Targets
Mitral Stenosis III: Medical Management
Venous Thrombosis III: Interprofessional Care

